Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Wellcome Flovent

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A head-to-head study in 533 asthma patients showed that fluticasone propionate was "significantly more effective" than Merck's leukotriene modifier Singulair (montelukast) in reducing asthma symptoms, improving lung function and reducing rescue albuterol use, Glaxo said. The study, presented at the Scientific Assembly of the American Academy of Family Physicians, compared 44 mcg (two puffs twice daily) Flovent to 10 mg once-daily Singulair for 24 week
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001201

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel